ArticleQuantitative imaging in medicine and surgery2025
Characteristic magnetic resonance imaging features of atypical spindle cell/pleomorphic lipomatous tumor.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Atypical Spindle Cell/Pleomorphic Lipomatous Tumor with Atypical Imaging Features.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic challenge of mixed tumors with adipocytic metaplasia of the finger: a rare case.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical spindle cell/pleomorphic lipomatous tumor (ASPLT) is a newly classified benign lipomatous neoplasm characterized by diverse histological features, leading to broad differential diagnoses. This study evaluated the magnetic resonance imaging (MRI) features of ASPLT to identify markers for distinguishing them from other soft tissue tumors. Nineteen patients with histologically confirmed ASPLT across multiple institutions were retrospectively evaluated. MRI features, including tumor margins, capsules, septa, fat content, hyperintense areas on T2-weighted imaging (T2WI), edema, and contrast enhancement were assessed by two experienced radiologists. Interobserver agreement was evaluated using Cohen's kappa coefficient. Fourteen men and five women [median age: 70 years; interquartile range (IQR), 62.5-74.5 years] were included, with common tumor sites including the femoral (seven) and thoracic dorsal (three) regions. The median lesion size was 90.0 mm (IQR, 48.5-135.7 mm). MRI revealed well-defined margins in 42.1% of patients, capsules in 89.5%, septa in 100%, and varied fat content. T2WI high-signal areas appeared in 94.7% of tumors. Contrast enhancement occurred in 93.8% of tumors, with 93.8% and 75% showing enhancement in fat-suppressed T2WI high- and low-signal areas, respectively. The interobserver agreement for key features ranged between moderate and good, with κ values of 0.42 for enhancement area [95% confidence interval (CI): 0.13-0.71], 0.57 for capsule presence (95% CI: 0.15-0.98), 0.60 for hyperintense areas on T2WI (95% CI: 0.35-0.85), and 0.64-0.89 for other features. Although κ=0.42 was classified as moderate, the wide confidence interval indicated variability in agreement. This study analyzed ASPLT imaging features, highlighting trends in fat and nonfatty components. ASPLT typically shows low-fat content on T1WI, T2WI high-signal areas, and varying degrees of contrast enhancement. Differential diagnoses included spindle cell lipoma, atypical lipomatous tumor/well-differentiated liposarcoma, dedifferentiated liposarcoma, and myxoid liposarcoma. Although pathological diagnosis remains crucial, recognizing imaging differences may enhance early diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.